Its strong connection to obesity and metabolic syndrome, two major risk factors for nonalcoholic fatty liver disease (NAFLD), has established chemerin as a possible biomarker and mediator in the mechanisms behind NAFLD and its advanced form, nonalcoholic steatohepatitis (NASH) [49]. This evidence concerns the gene RARRES2 and metabolic dysfunction-associated steatotic liver disease.